BDXBecton, Dickinson And Co.

BD to Announce Financial Results for its Third Quarter of Fiscal 2026 BD to Announce Financial Results for its Third Quarter of Fiscal 2026 PR Newswire FRANKLIN LAKES, N.J., July 9, 2026 FRANKLIN LAKES,N.J., July 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading...

Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

WST has surged nearly 33% YTD as strong earnings, GLP-1 demand and biologics growth fuel momentum that could extend through 2026.

ABT's Emerging Markets drive EPD growth, with strong branded generics demand, biosimilar expansion and new approvals boosting momentum.

BD Awarded Vizient Innovative Technology Contract for CentroVena One Insertion System BD Awarded Vizient Innovative Technology Contract for CentroVena One Insertion System PR Newswire FRANKLIN LAKES, N.J., June 23, 2026 Recognition from Vizient validates CentroVena One as a breakthrough innovation...

ABT falls 29.4% YTD as respiratory testing weakness, China uncertainty and acquisition dilution pressure results and outlook.

Becton, Dickinson's MedTech focus, innovation push and strategic partnerships support growth optimism, though reimbursement uncertainty remains a key concern.

ABT's Diagnostics unit witnesses mixed Q1 results as Core Lab growth offsets China weakness and softer respiratory testing demand.

BDX launches the Elyra Thulium Fiber Laser system to streamline kidney stone care and boost workflow flexibility for urology teams.